ZESTORETIC Drug Patent Profile

Which patents cover Zestoretic, and when can generic versions of Zestoretic launch?

Zestoretic is a drug marketed by Almatica and is included in one NDA.

The generic ingredient in ZESTORETIC is hydrochlorothiazide; lisinopril. There are thirty-two drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; lisinopril profile page.

Summary for ZESTORETIC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	120
Drug Prices:	Drug price information for ZESTORETIC
What excipients (inactive ingredients) are in ZESTORETIC?	ZESTORETIC excipients list
DailyMed Link:	ZESTORETIC at DailyMed

See drug prices for ZESTORETIC

See drug sales revenues for ZESTORETIC

Recent Clinical Trials for ZESTORETIC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Centre Hospitalier Universitaire de Saint Etienne	Phase 4
IPCA Laboratories Ltd.	Phase 1

See all ZESTORETIC clinical trials

Pharmacology for ZESTORETIC

Drug Class	Angiotensin Converting Enzyme Inhibitor Thiazide Diuretic
Mechanism of Action	Angiotensin-converting Enzyme Inhibitors
Physiological Effect	Increased Diuresis

US Patents and Regulatory Information for ZESTORETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-003	Nov 18, 1993	AB	RX	Yes	No
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-001	Sep 20, 1990	AB	RX	Yes	No
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	AB	RX	Yes	No

Expired US Patents for ZESTORETIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	4,374,829*PED
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-003	Nov 18, 1993	4,374,829*PED
Almatica	ZESTORETIC	hydrochlorothiazide; lisinopril	TABLET;ORAL	019888-002	Jul 20, 1989	4,472,380

International Patents for ZESTORETIC

See the table below for patents covering ZESTORETIC around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	1275349	DERIVES D'ACIDE AMINIQUE (AMINO ACID DERIVATIVES)
Zimbabwe	24479	AMINO ACID DERIVATIVES AS ANTIHYPERTENSIVES
Slovenia	7913000	PROCESS FOR OBTAINING DERIVATIVES OF CARBOXYALKYLDIPEPTIDES

Supplementary Protection Certificates for ZESTORETIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0503785	CA 2011 00026	Denmark		PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009

ZESTORETIC Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Zestoretic

Introduction to Zestoretic

Zestoretic, a combination drug consisting of lisinopril and hydrochlorothiazide, is widely used in the treatment of hypertension and other cardiovascular conditions. Understanding the market dynamics and financial trajectory of Zestoretic is crucial for pharmaceutical companies, investors, and healthcare providers.

Market Size and Growth

The global lisinopril market, which includes Zestoretic, has been experiencing steady growth. As of 2023, the lisinopril market was valued at approximately USD 226.46 million and is projected to reach USD 317.15 million by 2031, with a compound annual growth rate (CAGR) of 4.30% during the forecast period[1][4].

Drivers of Market Growth

Several factors are driving the growth of the Zestoretic market:

Rising Prevalence of Hypertension and Cardiovascular Diseases

The increasing global burden of hypertension and cardiovascular diseases is a primary driver. As lifestyles become more sedentary and dietary habits less healthy, the demand for antihypertensive medications like Zestoretic continues to rise. This trend is particularly pronounced in aging populations where cardiovascular issues are more prevalent[1].

Generic Versions and Cost-Effectiveness

The availability of generic versions of lisinopril, a key component of Zestoretic, at more affordable prices enhances market penetration. Generic versions offer a cost-effective solution for patients, healthcare providers, and payers, contributing significantly to the widespread adoption of these medications[1].

Increased Healthcare Expenditure

Growing healthcare expenditure in developing countries further extends profitable opportunities to market players. As healthcare systems invest more in managing chronic conditions, the demand for effective and affordable treatments like Zestoretic increases[1].

Market Segmentation

The market for Zestoretic is segmented based on several criteria:

By Disease

The hypertension segment is expected to dominate the market due to the greater usage of lisinopril in controlling hypertension. Other segments include heart failure, heart attack, strokes, diabetic kidney disease, and others[1].

By Dosage and Dosage Strength

Zestoretic is available in various dosages, including tablets and liquids, with different dosage strengths such as 10mg/12.5mg, 20mg/12.5mg, and 20mg/25mg[1].

By Population Type

The market is segmented into children and adults, with the adult population being the primary consumers of Zestoretic[1].

By End-Users

Hospitals, specialty clinics, home healthcare, and other end-users contribute to the market demand. The distribution channels include direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others[1].

Regional Analysis

The global lisinopril market, including Zestoretic, is analyzed across various regions:

North America

North America dominates the market due to the high prevalence of hypertension and cardiovascular diseases among the population. The U.S. and Canada are key markets in this region[1].

Asia-Pacific

The Asia-Pacific region is expected to grow at the highest rate during the forecast period, driven by an increasing geriatric population and growing healthcare expenditure in countries like Japan, China, and India[1].

Financial Performance

The financial performance of the lisinopril market, which includes Zestoretic, is robust:

Revenue Growth

The market is expected to grow from USD 226.46 million in 2023 to USD 317.15 million by 2031, indicating a steady increase in revenue over the forecast period[1].

CAGR

The CAGR of 4.30% during the forecast period from 2023 to 2031 reflects a stable and growing market[1].

Competitive Landscape

Major market players in the lisinopril market include pharmaceutical companies that manufacture both branded and generic versions of the drug. Companies like AstraZeneca, although not specifically mentioned as a manufacturer of Zestoretic, play a significant role in the broader pharmaceutical market and influence market dynamics through their product portfolios and strategic initiatives[2][3].

Innovations and Trends

Several trends are shaping the market for Zestoretic:

Innovations in Drug Delivery

There is a growing need for enhanced and patient-centric drug delivery approaches. Innovations in this area can improve patient adherence and overall treatment outcomes[4].

Cost-Effective Solutions

The demand for cost-effective solutions is increasing, driven by healthcare systems seeking to manage chronic conditions efficiently. Generic versions of lisinopril and combination drugs like Zestoretic are key in this regard[1][4].

Key Takeaways

• The global lisinopril market, including Zestoretic, is driven by the rising prevalence of hypertension and cardiovascular diseases.
• Generic versions and cost-effectiveness are significant factors in market growth.
• The market is segmented by disease, dosage, population type, end-users, and distribution channels.
• North America dominates the market, while the Asia-Pacific region is expected to grow at the highest rate.
• The market is expected to grow at a CAGR of 4.30% from 2023 to 2031.

FAQs

What is the current market size of the lisinopril market?

The lisinopril market was valued at approximately USD 226.46 million in 2023[1].

What is the projected growth rate of the lisinopril market?

The market is expected to grow at a CAGR of 4.30% from 2023 to 2031[1].

Which segment dominates the lisinopril market?

The hypertension segment is expected to dominate the market due to the greater usage of lisinopril in controlling hypertension[1].

What are the key drivers of the lisinopril market growth?

The key drivers include the rising prevalence of hypertension and cardiovascular diseases, the availability of generic versions, and increased healthcare expenditure in developing countries[1].

Which region is expected to grow at the highest rate in the lisinopril market?

The Asia-Pacific region is expected to grow at the highest rate during the forecast period[1].

Cited Sources

1. Data Bridge Market Research, Global Lisinopril Market – Industry Trends and Forecast to 2031.
2. AstraZeneca, AstraZeneca Annual Report 2005.
3. AstraZeneca, What science can do - Annual Reports.
4. GII Research, Lisinopril Global Market Report 2024.